Researchers from Kevirx Inc. and collaborators have described the use of KVX-053, a PTP4A3 inhibitor aimed to be used for the prevention of COVID-19-associated cute lung injury (ALI).
In a recently published study, researchers from Cima Universidad de Navarra and collaborators presented a novel SdAb-based CAR T-cell discovery platform that allows the generation, characterization and selection of SdAbs by several properties.
Septerna Inc. has announced its decision to discontinue a healthy volunteer phase I trial of SEP-786, an oral small-molecule agonist of the parathyroid hormone 1 receptor being developed for the treatment of hypoparathyroidism.
Cystic fibrosis is a life-threatening disease predominantly with respiratory symptoms. Most of the subjects with the disease harbor the F508del variant in the CFTR gene that causes the protein to misfold and be prematurely degraded. Despite approved drugs that restore the CFTR protein, the maximal lung function improvement is approximately 14%.
Kairos Pharma Ltd. has announced that through its academic partnership with Cedars-Sinai Medical Center, Cedars-Sinai has received $600,000 in funding from the Department of Defense lung cancer research program to advance the development of ENV-205, a new drug to treat chemotherapy drug resistance and cachexia.
In a recent publication in Cell, researchers from the National University of Singapore and collaborators have proposed using commensal bacteria in the nasal cavity as a delivery vector for precision therapy targeting the OE and brain.
Perceive Pharma Inc., a spin out from Perceive Biotherapeutics Inc., has closed a $15 million series A funding round to help it advance first-in-class therapies to prevent vision loss in glaucoma, and additional undisclosed disease areas.
Using ALK+ lung cancer patient-derived cell lines, researchers have performed phosphoproteomic screening and identified guanylate kinase 1 (GUK1) as a TKI sensitive metabolic molecule in ALK-driven lung cancer. They reported their results online in Cell on Feb. 6, 2025.
Canwell Biotech Ltd. has described antibody-drug conjugates (ADCs) comprising an antibody covalently linked to a Toll-like receptor 7 (TLR7) and TLR8 agonist through a cleavable or noncleavable linker reported to be useful for the treatment of cancer, allergy, autoimmune diseases, immunodeficiency disorder, sepsis and infections.
Shenzhen Zhongge Biotechnology Co. Ltd. has divulged AMP-activated protein kinase α1β1γ1 activators reported to be useful for the treatment of acute kidney injury, alopecia, chronic kidney disease, type 2 diabetes, diabetic nephropathy, dyslipidemia and obesity.
RSS
